Immunome Q3 net loss widens, expects current cash to fund operations into 2027

Immunome

06/11/2025 22:03

Overview

Immunome reports Q3 net loss of $57.5 mln,

Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027

Research and development expenses for Q3 were $49.2 mln

Outlook

Varegacestat: Immunome expects to report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025

Immunome expects current cash to fund operations into 2027

Result Drivers

R&D INVESTMENT - Significant investment in R&D with expenses totaling $49.2 mln for Q3

General and administrative expenses- General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$57.46 mln
Q3 Income From Operations
-$60.14 mln
Q3 Operating Expenses
$60.14 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Immunome Inc is $23.50, about 34.7% above its November 5 closing price of $15.35

Press Release: ID:nBw2ZyRqwa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)